Rachelle joined Enzyvant as CEO from Alexion Pharmaceuticals, Inc., where she most recently served as Senior Vice President and Global Franchise Head of Complement across therapeutic areas of hematology, nephrology, and neurology. She brings broad experience in US and Global commercial leadership, including multiple high-profile product launches in rare diseases. Previously, Rachelle was Vice President of U.S. Hematology Marketing at Shire plc, which acquired Baxalta Inc. (“Baxalta”) in 2016 and served as Vice President of Business Operations at Baxalta after its spinoff from Baxter International Inc. (“Baxter”) in 2015. At Baxter, Ms. Jacques held multiple leadership positions, including Vice President of Finance, U.S. Bioscience Business and Vice President, Business Operations for the Global Bioscience Business Unit. Earlier in her career, Ms. Jacques served in various roles of increasing responsibility at Dow Corning Corporation, including U.S. and international operational management roles. Rachelle has lived and worked in the US, Belgium, and China. She started her career in finance and earned a Bachelor of Arts degree in Business Administration with an emphasis in accounting from Alma College. Rachelle also serves on the boards of Corbus Pharmaceuticals and Viela Bio.